Xilio Therapeutics Virtual Program Spotlight on XTX301: A Tumor-Activated IL-12

Back to Events


Please join Xilio Therapeutics for a virtual program spotlight on XTX301:A Tumor-Activated IL-12 featuring Key Opinion Leader (KOL) Diwakar Davar, MBBS, M.Sc (UPMC Hillman Cancer Center), who will discuss the current landscape and unmet medical need present in treating patients with advanced solid tumors and Xilio’s potential therapeutic solution, XTX301

The Xilio leadership team will highlight the optimization of IL-12 for therapeutic use and how XTX301 overcomes the existing challenges of severe system toxicity associated with the use of unmodified IL-12. Through a protein-engineered masking domain, XTX301 is selectively activated in the tumor microenvironment (TME), only then releasing the active IL-12 cytokine.

A live question and answer session will follow.

The post Xilio Therapeutics Virtual Program Spotlight on XTX301: A Tumor-Activated IL-12 appeared first on LifeSci Events.